文献速递心境障碍焦虑、强迫与应激相关障碍

优化与个性化任务分担心理社会干预:贝叶斯组分网络荟萃分析

Optimising and personalising task-shared psychosocial interventions for common mental disorders: a Bayesian component network meta-analysis of individual participant data.
PubMed 文献 · Lancet Psychiatry · 2026-08-03

BACKGROUND: Although psychosocial interventions delivered by non-specialist providers effectively treat common mental disorders such as depression and anxiety, the treatment-specific elements driving their efficacy remain largely unknown.…

要点

  • 加强社会支持、行为激活和问题管理是任务分担心理社会干预中最有益的组分。
  • 放松和认知重构可能产生不利效应,需谨慎使用。
  • 组分效应随基线严重程度和社会人口学特征系统性变化,可个性化预测。

核心结论

  • 加强社会支持、问题管理和行为激活在成人抑郁或焦虑的任务分担心理社会干预中带来最大增量获益。

研究设计与样本

  • 检索MEDLINE、Embase、PsycINFO和CENTRAL从建库至2023年3月15日,并纳入截至2026年5月29日发表的额外数据集及未发表RCT。
  • 使用专门构建的治疗特异性元素分类法将干预拆解为组分,主要结局为研究终点时常见精神障碍症状减轻的疗效。

主要发现

  • 交互分析显示组分效应随基线严重程度和其他社会人口学特征系统性变化。

关键数值与推荐

  • 使用修订版Cochrane风险偏倚工具评估纳入研究的偏倚风险。
  • 个性化效应估计可通过免费公开的网页应用计算。

临床怎么用

  • 在任务分担心理社会干预中优先纳入加强社会支持、问题管理和行为激活组分。
  • 谨慎使用放松和认知重构组分,因其可能产生不利效应。
  • 可利用免费网页应用基于个体特征计算个性化效应估计。

局限性

  • 种族数据不可用。
  • 仅30项试验(89%)提供了个体参与者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although psychosocial interventions delivered by non-specialist providers effectively treat common mental disorders such as depression and anxiety, the treatment-specific elements driving their efficacy remain largely unknown. Our aim was to compare and rank the efficacy of the individual active components of task-shared psychosocial interventions and to predict efficacy using individual participant characteristics. METHODS: We performed a systematic review and Bayesian individual participant data component network meta-analysis of RCTs comparing different task-shared psychosocial interventions with control conditions for the treatment of adults with common mental disorders. We searched MEDLINE, Embase, PsycINFO, and CENTRAL from database inception to March 15, 2023. We included additional datasets published up to May 29, 2026 and unpublished RCTs. We sought individual participant data from the trial authors. A purpose-built taxonomy of treatment-specific elements was used to dismantle interventions into their constituent components. The primary outcome was efficacy in reducing symptoms of common mental disorders, as measured at study endpoint. We used incremental mean difference to indicate the added benefit (or detrimental effect) of adding a component to a treatment. We assessed the risk of bias of the included studies with the revised Cochrane Risk of Bias tool. The protocol was published in a peer-reviewed journal. FINDINGS: We included 34 RCTs, from which 30 trials (89%) contributed individual participant data from 10 612 participants. Of these participants, 7662 were women (72·2%) and 2950 were men (27·8%). The mean age of participants was 36·7 years (SD 5·5). Findings identified strengthening social support (incremental mean difference -9·48; 95% credible interval [CrI] -13·29 to -6·60), behavioural activation (-4·15; -7·48 to -0·05), and problem management (-4·08; -5·37 to -2·83) as the most beneficial components. Relaxation (7·97; 3·35 to 12·11) and, less clearly, cognitive reframing (5·17; 0·78 to 9·15) were identified as detrimental components. Interaction analyses revealed that component effects vary systematically by baseline severity and other sociodemographic characteristics. Ethnicity data were not available. Individuals with lived experience contributed to the interpretation of results. Personalised effect estimates can be computed via a freely accessible web application. INTERPRETATION: Strengthening social support, problem management, and behavioural activation were associated with the greatest incremental benefit within task-shared psychosocial interventions for adults with depression or anxiety. FUNDING: European Commission.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Papola D, Tedeschi F, Efthimiou O, et al. Optimising and personalising task-shared psychosocial interventions for common mental disorders: a Bayesian component network meta-analysis of individual participant data. Lancet Psychiatry. 2026. PMID: 42546730. doi:10.1016/S2215-0366(26)00193-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。